Mianserin hydrochloride Property

Melting point:

>230oC (dec.)

Flash point:

9℃

storage temp. 

2-8°C

solubility 

H₂O: 3.4 mg/mL

form 

Solid

color 

Off-White to Pale Yellow

Water Solubility 

Soluble in water, ethanol, methanol, and dimethylformamide.

Merck 

14,6172

InChIKey

YNPFMWCWRVTGKJ-UHFFFAOYSA-N

CAS DataBase Reference

21535-47-7(CAS DataBase Reference)

Safety

Hazard Codes 

Xn,Xi,T,F

Risk Statements 

22-39/23/24/25-23/24/25-11

Safety Statements 

7-16-36/37-45

RIDADR 

3249

WGK Germany 

3

RTECS 

HP8780000

HS Code 

2933.59.8000

HazardClass 

6.1(b)

PackingGroup 

III

Toxicity

LD50 in male, female mice (mg/kg): 365, 390 orally; 32.5, 31.0 i.v. (van Riezen)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Mianserin hydrochloride Chemical Properties,Usage,Production

Chemical Properties

Off-White Solid

Originator

Tolvin,Organon,W. Germany,1975

Uses

Mianserin hydrochloride is a tetracyclic antidepressant with an EEG and clinical activity profile similar to amitriptyline. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.

Uses

Mianserin hydrochloride is used as an antidepressant, antagonist, inverse agonist at 5-HT2 serotonin receptors, also blocks the H1 histamine receptor and the α2 adrenoceptor.

Manufacturing Process

(A) 25 g of 2-benzylaniline dissolved in 150 ml of benzene are cooled down in an ice bath to 8°C. To this solution are added 15 ml of pyridine and after that a solution of 15 ml of chloroacetyl chloride in 25 ml of benzene, maintaining the temperature of the reaction mixture at 10° to 15°C. After stirring for 1 hour at room temperature 25 ml of water are added and the mixture is shaken for 30 minutes. Next the mixture is sucked off and the benzene layer separated. Then the benzene layer is washed successively with 2 N HCl, a sodium carbonate solution and water. The extract dried on sodium sulfate is evaporated and the residue crystallized together with the crystals obtained already from benzene. Yield 18 g; MP 130° to 133°C.
(B) 40 g of N-chloroacetyl-2-benzylaniline are heated for 2 hours at 120°C together with 50 ml of phosphorus oxychloride and 320 g of polyphosphoric acid. Next the reaction mixture is poured on ice and extracted with benzene. The extract is washed and dried on sodium sulfate and the benzene distilled off. The product obtained (31g) yields after recrystallization 24 g of 6- chloromethyl-morphanthridine of MP 136° to 137°C.
(C) 10 g of 6-chloromethyl-morphanthridine are passed into 150 ml of a solution of methylamine in benzene (10%). After storage of the solution for 20 hours at 0° to 5°C the methylamine hydrochloride formed is sucked off and the filtrate evaporated to dryness. There remains as residue 11 g of crude 6-methylaminomethyl-morphanthridine.
(D) 11 g of crude 6-methylaminomethyl-morphanthridine are dissolved in 50 ml of absolute ether. While cooling in ice 2.7 g of lithium aluminumhydride, dissolved in 100 ml of absolute ether, are added. After boiling for 1 hour and cooling down in ice 11 ml of water are added slowly dropwise while stirring. After stirring for another 30 minutes at room temperature the mixture is sucked off and the filtrate evaporated to obtain 11 g of crude 5,6-dihydro-6- methylaminomethyl-morphanthridine in the form of a light yellow oil.
(E) 10 g of 5,6-dihydro-6-methylaminomethyl-morphanthridine are heated slowly, in 30 minutes, from 100° to 160°C with 7 g of pure diethyloxalate and after that from 160° to 180°C in 45 minutes. After cooling down the reaction mixture is stirred with benzene. The crystals are sucked off and yield after crystallization from dimethylformamide 9 g of 1,2-diketo-3(N)-methyl- 2,3,4,4a-tetrahydro-1H-pyrazino-[1,2-f]-morphanthridine of MP 245° to 247°C.
(F) 9 g of the diketo-pyrazino-morphanthridine compound obtained above are reduced with diborane to give mianserin.

Therapeutic Function

Serotonin antagonist, Antihistaminic

Biological Activity

Mianserin hydrochloride is a non-selective 5-HT2 receptor antagonist (Ki values are 0.0080 and 0.0081 μM for human 5-HT2A and 5-HT2C receptors expressed in HEK293 cells respectively). Has moderate affinity for 5-HT6. Antidepressant.

Clinical Use

Antidepressant

Drug interactions

Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Antibacterials: avoid with linezolid and tedizolid. Antidepressants: avoid with MAOIs and moclobemide.
Antiepileptics: convulsive threshold possibly lowered; concentration reduced by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone.
Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol.
Safinamide: increased risk of hypertension and CNS excitation.

Metabolism

Mianserin is hepatically metabolised via aromatic hydroxylation, N-oxidation and N-demethylation. There are 3 urinary metabolites, (N-desmethyl, 8-hydroxy, and N-oxide derivative) which have been identified. The desmethyl metabolite, which is also active, has similar pharmacokinetic behaviour as the parent compound. Mianserin is excreted in the urine, almost entirely as its metabolites, either free or in conjugated form; 14-28% in the faeces.

storage

Room temperature